Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTRISIN versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTRISIN versus SULLA.
AZO GANTRISIN vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a competitive inhibitor of dihydropteroate synthase, blocking bacterial folic acid synthesis. Phenazopyridine is an azo dye with local analgesic effects on urinary tract mucosa.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
AZO GANTRISIN (phenazopyridine 100 mg / sulfisoxazole 500 mg): 2 tablets orally 4 times daily for 2 days, then 1 tablet 4 times daily for up to 5 days.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Sulfamethoxazole: 9-12 hours (adults with normal renal function), prolonged to 20-50 hours in renal impairment; trimethoprim component: 8-11 hours. Clinical context: dosing interval adjusted based on CrCl.
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 70-100% (sulfamethoxazole and metabolites; 15-30% as unchanged drug; remainder as acetylated and glucuronide conjugates). Biliary/fecal: <3%.
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic